
    
      This trial is a phase 3, multicenter, randomized, double-blind, placebo controlled, parallel
      group study comparing the safety and efficacy of daily dosing of MPC-7869 to placebo. The
      study subjects will have the diagnosis of mild dementia of the Alzheimer's type. Subjects may
      be taking approved medication for Alzheimer's disease provided the dose has been stable for
      at least 6 months.

      The primary objective of the study is to evaluate the change in cognition and activities of
      daily living.
    
  